Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brandicourt Not Ready To Raise Medivation Bid Just Yet

Executive Summary

Sanofi has reiterated its interest in the acquisition of Medivation and the French pharma's CEO has toughened up his language. Meanwhile, despite lots of speculation about other potential suitors, none has yet to come forward publicly.

You may also be interested in...



Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations

After two months of public, hostile back-and-forth, Sanofi agreed to confidentially discuss a potential acquisition of Medivation, putting the French pharma on equal footing with the biotech company's other suitors.

Sanofi Seeks Medivation Board Overhaul As Buyout Bid Remains Rejected

Sanofi is putting more pressure on Medivation to accept its $9.3bn acquisition offer by proposing to replace the biotechnology company's and Xtandi developer's entire board of directors.

Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole

Pfizer Inc. has made its first M&A move since the planned mega-deal with Allergan PLC collapsed. The big pharma announced May 16 that it will buy Anacor Pharmaceuticals Inc. for $99.25 per share in cash, or approximately $5.2bn.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC065117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel